Attralus

Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (Daratumumab and Hyaluronidase-fihj) for the Treatment of Patients With Light Chain (AL) Amyloidosis

Amyloidosis Support Groups Webinar on AL Amyloidosis

Mayo Clinic Patient Symposium in Plasma Cell Disorders 2021: Patient and Family Registration

Diet and Nutrition in AL Amyloidosis

Understanding Light Chain Amyloidosis

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis

Shayna R. Sarosiek, MD

Marina Ramirez-Alvarado, PhD

@Jmarksloan

Vaishali Sanchorawala, MD

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Learn More

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion